Restart Life Sciences Corp.
NMLSF
$0.06
-$0.02-21.16%
OTC PK
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -75.57% | 126.88% | |||
| Depreciation & Amortization | 0.00% | -25.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -75.70% | 128.30% | |||
| Operating Income | 75.70% | -128.30% | |||
| Income Before Tax | 74.22% | -570,600.00% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 74.22% | -570,600.00% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 74.22% | -570,600.00% | |||
| EBIT | 75.70% | -128.30% | |||
| EBITDA | 75.75% | -128.55% | |||
| EPS Basic | 79.34% | -- | |||
| Normalized Basic EPS | 80.19% | -32.50% | |||
| EPS Diluted | 66.20% | -280.36% | |||
| Normalized Diluted EPS | 80.19% | -47.22% | |||
| Average Basic Shares Outstanding | 25.67% | 60.31% | |||
| Average Diluted Shares Outstanding | 25.67% | 44.49% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||